GridAI Technologies GRDX

GridAI Technologies Corp is engaged in the research and development of targeted non-systemic therapies for gastrointestinal diseases and operates Grid AI an artificial intelligence driven energy technology platform acquired on September 30 2025 which provides software to optimize and coordinate distributed energy resources.

GridAI Technologies Corp generates revenue from product sales of its therapeutic candidates and from the Grid AI platform which offers software solutions for managing distributed energy resources to utilities energy retailers and large commercial and industrial customers.

The company operates through the following segments: Biotechnology and Grid AI.

• Biotechnology focuses on developing oral non-systemic biologic therapies such as Adrulipase for exocrine pancreatic insufficiency in cystic fibrosis and chronic pancreatitis patients and previously worked on programs for celiac disease gastroparesis and inflammatory bowel diseases which have been discontinued or are being disposed of.
• Grid AI through its subsidiary AmpX provides an artificial intelligence based orchestration platform that integrates with grid and on-site infrastructure to support automated load management distributed generation optimization and real-time energy system coordination using machine learning models to improve reliability reduce operating costs and support renewable energy adoption.

GridAI Technologies Corp operates in the competitive biotechnology and energy technology sectors where it faces competition from established pharmaceutical companies developing gastrointestinal therapies and from other AI driven energy management platforms offering grid edge solutions.

The company serves patients with gastrointestinal conditions such as cystic fibrosis chronic pancreatitis and celiac disease through its biotechnology segment and utilities energy retailers and large commercial and industrial customers through its Grid AI segment.